论文部分内容阅读
目的探讨血清CA125测定对子宫内膜异位性疾病患者的临床价值。方法选取2009年1月—2013年1月鹤壁市人民医院收治的子宫内膜异位症患者53例(A组),子宫腺肌病患者39例(B组),卵巢良性肿瘤患者27例(C组),子宫肌瘤患者64例(D组),正常孕龄期妇女38例(E组),用化学发光免疫法分别检测各组患者血清CA125的水平并进行比较。结果五组患者的血清CA125阳性率分别是73.58%、66.67%、11.11%、14.06%、5.26%,A、B组患者明显高于C、D、E三组患者,差异具有统计学意义(P<0.05)。子宫内膜异位症分期显示I、Ⅱ期患者与ⅡI、IV期患者同样存在明显差异(P<0.05)。结论血清CA125测定可作为子宫内膜异位症、子宫腺肌病、卵巢良性肿瘤和子宫肌瘤的鉴别诊断依据。
Objective To investigate the clinical value of serum CA125 in patients with endometriosis. Methods 53 patients with endometriosis (group A), 39 patients with adenomyosis (group B) and 27 patients with benign ovarian tumor (group B) were selected from January 2009 to January 2013 in Hebi City People’s Hospital. C group), 64 cases of uterine fibroids (group D) and 38 women of normal gestational age (group E). The levels of serum CA125 in each group were detected by chemiluminescence immunoassay and compared. Results The positive rates of serum CA125 in the five groups were 73.58%, 66.67%, 11.11%, 14.06% and 5.26% respectively. The patients in group A and B were significantly higher than those in groups C, D and E (P <0.05). Staging of endometriosis showed that there were also significant differences between stage I and II patients and stage III and IV patients (P <0.05). Conclusion Serum CA125 determination can be used as the basis of differential diagnosis of endometriosis, adenomyosis, benign ovarian tumor and uterine fibroids.